APLS Q2 2022 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+2519.9% YoY

Gross Profit

$16M99.5% margin

Operating Income

-$149M-910.6% margin

Net Income

-$156M-955.6% margin

EPS (Diluted)

$-1.46

QoQ Revenue Growth

+13.5%

Cash Flow

Operating Cash Flow

-$107M

Free Cash Flow

-$107M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$668M

Stockholders' Equity

$334M

Cash & Equivalents

$604M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$623,000	+2519.9%
Gross Profit	$16M	$623,000	+2506.7%
Operating Income	-$149M	-$194M	+23.5%
Net Income	-$156M	-$219M	+28.8%

Revenue Segments

Product

$16M96%

Licensing And Other Revenue

$668,0004%